A5077052809- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Nutrition and Health in Aging
- Cancer Mechanisms and Therapy
- Homelessness and Social Issues
- Neutropenia and Cancer Infections
- Cutaneous Melanoma Detection and Management
- Colorectal Cancer Screening and Detection
- HIV, Drug Use, Sexual Risk
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HIV/AIDS Research and Interventions
- Sex and Gender in Healthcare
- Neuroscience and Neuropharmacology Research
- Cancer-related molecular mechanisms research
- PARP inhibition in cancer therapy
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Liver physiology and pathology
- Diabetes Management and Education
Harbin Medical University
2025
University of Calgary
2021-2024
University of Alberta
2021-2023
University Health Network
2020-2022
Princess Margaret Cancer Centre
2020-2022
University of Toronto
2019-2020
Alberta Health Services
2020
KCNH2 encodes the hERG potassium channel, which is associated with drug-induced long QT syndrome. Arsenic trioxide (ATO) an effective therapeutic agent for acute promyelocytic leukemia; however, its long-term use can lead to cardiotoxicity, particularly in cases of acquired syndrome (acLQTS), may result torsade de pointes (TdP). Therefore, it essential comprehend mechanisms behind acLQTS and develop preventive strategies. This study sought investigate role molecular mechanism MALAT1...
The emergence of immunotherapy revolutionized the treatment non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing efficacy these agents. However, many patients who receive in practice would be considered trial ineligible. One such population that is often under-represented older adults. In current study, we evaluated and safety outcomes this population. Overall, adults (>70 years age) younger had comparable an equivalent objective response rate (ORR), time...
4098 Background: Advances in systemic therapy for HCC have increased treatment options, including TKIs and immunotherapy combinations. Variables that predict patient outcomes may be helpful personalizing decisions. The aim of this study was to identify predictors short-term death (STD) long-term survival (LTS) patients. Methods: Retrospective review patients with advanced who received a TKI or combinations conducted between Aug 2018 2022 the Canadian provinces British Columbia, Alberta, Nova...
Abstract Background Lenvatinib (LEN) and atezolizumab + bevacizumab (A B) have drastically changed the treatment paradigm for advanced hepatocellular carcinoma (HCC). Before these landmark trials, sorafenib (SOR) served as standard first‐line a decade. Our study aimed to assess outcomes of HCC patients treated during SOR era (2008–2018) in contrast those post‐SOR (2018–2021), which predominant treatments were LEN or A B. Methods Inclusion criteria all Canadian province Alberta who started...
The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric varices. necessity mandatory EGD all patients remains unclear. We retrospectively analyzed 112 HCC treated A+B at five Canadian cancer centers July 1, 2020, August 31, 2022. was the first-line therapy 90% patients, median overall survival 20.3...
The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric varices. necessity mandatory EGD all patients remains unclear. We retrospectively analyzed 112 HCC treated A+B at five Canadian cancer centers 1 July 2020 31 August 2022. was the first-line therapy 90% patients, median overall survival 20.3 and...
4111 Background: Lenvatinib (LEN) and the combination of atezolizumab with bevacizumab (AB) are widely considered first-line systemic therapies for treatment advanced hepatocellular carcinoma (HCC), but have never been compared directly in a randomized clinical trial. Cross-trial comparisons between IMbrave150 LEAP-002 appear to show similar survival outcomes AB LEN, respectively, while LEN was shorter REFLECT Methods: Patients treated or HCC from August 2018 2022 Canadian provinces British...
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens' effectiveness. We retrospectively analyzed 402 unresectable metastatic melanoma between August 2013 July 2020 treated immune targeted therapy in Alberta, Canada. Overall (OS) was compared using Kaplan-Meier Cox regression analyses. Subgroup outcomes were by first-line treatment regime BRAF mutation status. Three eras...
Abstract Background Colorectal cancer remains the second leading cause of death in North America. Fluorouracil and oxaliplatin based adjuvant chemotherapy for resected colon (CC) reduces recurrence, but also causes significant toxicity requiring dose reductions. The effect intensity on survival outcomes is not fully understood strengthening evidence supports informed decision making between patients oncologists. Methods Patients treated with chemotherapy, 2006 2011, at four Canadian academic...
: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied reporting differences survival outcomes amongst different age groups.
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset patients. However, outcomes remain poor non-responders. Clinical predictors long-term elusive. We utilized the Alberta Immunotherapy Database to investigate association host and disease characteristics, factors with greater than 3 years. identified patients treated between August 2013 May 2020 single-agent anti-PD1 or combination (anti-PD1 anti-CTLA4) ICI...
PURPOSE The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration showed no significant clinical difference in outcomes patients with stage III colon cancer (CC) treated 3 versus 6 months oxaliplatin-based adjuvant chemotherapy (O-ACT). We aimed to assess change real-world practice patterns before and after publication the IDEA study. METHODS This retrospective cohort study included age ≥18 years CC diagnosed between January 1, 2012, December 31, 2020. Eligible...
4105 Background: The IMbrave150 trial established A+B as a standard of care for HCC and an EGD within 6 months (mos) starting treatment to detect esophagogastric varices prevent bleeding complications was advised. However, the value performing in all patients (pts) is unknown. Methods: We conducted retrospective analysis pts treated with between July 2020 August 2022 at 5 cancer centres from Canadian provinces Ontario, Alberta Manitoba (members HCC-CHORD Consortium). Pts characteristics...
e18511 Background: Prior research has linked patient-physician sex discordance with inferior surgical and cardiac outcomes. The impact of such inequities may be magnified in medical oncology, where patients often face a life-limiting illness physicians assume the role primary healthcare provider. This study examined cancer treatment practices survival outcomes sex-concordant vs. discordant dyads. Methods: was population-based, retrospective cohort adults diagnosed stage II-IV colon or lung...
The management of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is limited remains an unmet need. Decitabine/cedazuridine (DEC-C, ASTX727) Canada’s first only approved oral hypomethylating agent for MDS CMML. We characterized the real-world use DEC-C through a Canadian compassionate program. Demographic clinical data from 769 patients enrolled in Taiho Pharma Patient Support Program were collected analyzed. These represent collection period 10 November 2020 to 31...
Background: There are limited published data in the Canadian healthcare system on use of granulocyte colony-stimulating factor (G-CSF) among patients with breast cancer. This study characterized real-world G-CSF during period surrounding introduction filgrastim biosimilar. Methods: Electronic medical records were reviewed retrospectively for cancer who received moderately or highly myelosuppressive (neo)adjuvant chemotherapy from 2008 to 2019 Alberta, Canada. Trends usage plotted elucidate...
Background: Gastric cancer mortality remains among the highest of all cancers. Trifluridine/tipiracil (FTD/TPI) represents Canada’s first standard-of-care, third-line, systemic therapy for metastatic gastric/gastroesophageal cancer. We characterized real-world treatment patterns in patients enrolled to receive FTD/TPI through Taiho Pharma Patient Support Program. Methods: Demographic and clinical information were collected from November 2019 2021 adult with refractory throughout Canada....
553 Background: SOR was the standard first-line treatment for HCC about a decade until approval of LEN. Subsequently, atezolizumab + bevacizumab (A+B) were shown to have superior efficacy outcomes. The aim this study compare effectiveness outcomes patients treated in era compared post-SOR era, when most received LEN or A+B. Methods: All who started systemic therapy at cancer centres Canadian province Alberta between January 1, 2008 and December 31, 2021 included study. Overall survival (OS),...
Surveillance of stage IV colorectal cancer (CRC) after curative-intent metastasectomy can be effective for detecting asymptomatic recurrence. Guidelines various forms surveillance exist but are supported by limited evidence. We aimed to determine the most cost-effective strategy following CRC. performed a decision analysis compare four active strategies involving clinic visits and investigations elicited from National Comprehensive Cancer Network (NCCN) recommendations. Markov model inputs...